Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Tech Journal.
Press releases published on August 11, 2025
Rail Vision Receives European Patent for Innovative Locomotive Imaging Technology
GlobeNewswire
·
August 11, 2025
Ra’anana, Israel, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company seeking to revolutionize railway safety and the data-related market, today announced …
Altimmune Board of Directors Appoints Jerry Durso as Chairman
GlobeNewswire
·
August 11, 2025
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) …
Avicanna Announces US Patent and Trademark Office Issuance of New Patent
GlobeNewswire
·
August 11, 2025
USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on …
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
GlobeNewswire
·
August 11, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial …
SixSense Raises $8.5M Funding to Power AI-Driven Semiconductor Manufacturing
GlobeNewswire
·
August 11, 2025
SINGAPORE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- SixSense, a pioneer in AI for semiconductor manufacturing, announced a new round of funding led by Peak XV’s Surge (formerly Sequoia India …
SixSense 獲得 850 萬美元資金以推動 AI 驅動的半導體製造
GlobeNewswire
·
August 11, 2025
新加坡, Aug. 11, 2025 (GLOBE NEWSWIRE) -- SixSense，一家半導體製造領域的 AI 先驅，宣佈了新的資金將由 Peak XV 的 Surge（前身為 Sequoia India …
Plum Role Model™ Named a 2025 Top HR Product of the Year by HR Executive
GlobeNewswire
·
August 11, 2025
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revolutionary pre-hire assessment provider Plum today announced that its newest innovation, Plum Role Model™, has been recognized as a Top HR Product of 2025 by HR Executive. The company will be honored on Monday …
Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia Production Facility This Week
GlobeNewswire
·
August 11, 2025
ANN ARBOR, Mich., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it will begin operations this week at its newest production facility. …
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
GlobeNewswire
·
August 11, 2025
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private …
BioCryst Announces Departure of Dr. Helen Thackray
GlobeNewswire
·
August 11, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an …
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
GlobeNewswire
·
August 11, 2025
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studies Trial initially taking place in the U.S., following IND clearance Initial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumors …
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
·
August 11, 2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track …
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month maintenance dosing, a …
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
GlobeNewswire
·
August 11, 2025
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments, with …
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GlobeNewswire
·
August 11, 2025
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans on releasing initial Phase 1 results …
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
GlobeNewswire
·
August 11, 2025
BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phase 3 study in …
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
GlobeNewswire
·
August 11, 2025
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 million CARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining progression-free for ≥5 years Presented other …
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 11, 2025
- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement - - 82 civilian hospitals now have VAC approval to purchase Symvess™ - - ECAT approval makes Symvess available to 35 …
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
GlobeNewswire
·
August 11, 2025
Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025 All other clinical trials in previously announced six-indications …
Harvard Bioscience Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 11, 2025
Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by Operations Third Quarter 2025 Guidance Reflects Improved Operations and Strong Financial Discipline New Credit Amendment Signed, Extending Refinance Deadline to …